FDMT · CIK 0001650648 · operating
A late-stage biotechnology company developing adeno-associated virus (AAV) vectors derived from its proprietary Therapeutic Vector Evolution platform. 4D Molecular Therapeutics focuses on gene therapy candidates designed to address genetic and degenerative diseases through sustained therapeutic protein production. The company's pipeline spans multiple therapeutic areas, including ophthalmology, pulmonology, genetic metabolic disorders, and rare genetic diseases.
The lead program, 4D-150, targets retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema, with the mechanism designed to deliver multi-year sustained anti-VEGF production via intravitreal injection. Additional candidates in development include 4D-710 for cystic fibrosis in early-stage clinical study, 4D-175 for geographic atrophy in preclinical stage, 4D-725 for alpha-1 antitrypsin deficiency in preclinical stage, and 4D-310 for Fabry disease in Phase 1 clinical trial. The company maintains research and development operations in both the Netherlands and the United States.
4D Molecular Therapeutics operates with 227 full-time employees and maintains collaboration and licensing agreements with Astellas Gene Therapies, Arbor Biotechnologies, and uniQure biopharma. The company was incorporated in Delaware and is headquartered in Emeryville, California, with its stock listed on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.98 | $-2.98 | -15.5% | |
| 2023 | $-2.58 | $-2.58 | +22.3% | |
| 2022 | $-3.32 | $-3.32 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |